Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma
Latest Information Update: 10 Aug 2022
At a glance
- Drugs Cabozantinib (Primary) ; Dacarbazine; Temozolomide
- Indications Uveal melanoma
- Focus Therapeutic Use
- 26 Sep 2019 Primary endpoint (Proportion of Patients Without a Progression Free Survival Event at 4 Months (PFS4) has not been met published in the Clinical Cancer Research
- 26 Sep 2019 Status changed from active, no longer recruiting to discontinued.
- 26 Sep 2019 Interim results assessing the progression-free survival rate at 4 months of patients with uveal melanoma treated with cabozantinib or chemotherapy published in the Clinical Cancer Research